Remove 2016 Remove Regulations Remove RNA
article thumbnail

Malaria unravelled: decoding the parasite’s gene expression control

Drug Target Review

Researchers from Tokyo Tech’s World Research Hub Initiative conducted a study to investigate the regulation of gene expression in the apicoplast of the malaria parasite Plasmodium falciparum. Through phylogenetic analysis and microscopy techniques, they identified a nuclear-encoded apicoplast RNA polymerase σ subunit called ApSigma.

RNA 98
article thumbnail

A Molecular Portrait of ALS and FTD

Drug Target Review

14 TDP-43 is a DNA and RNA binding protein that regulates the expression and splicing of several target transcripts. Many potential toxic effects have been suggested, including the mis-splicing of the Stathmin-2 RNA transcript. 14 Image modified from Suk et al.

RNA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GRouNdGAN: GRN-guided simulation of single-cell RNA-seq data using causal generative adversarial networks

Broad Institute

Through the imposition of a user-defined GRN in its architecture, GRouNdGAN simulates steady-state and transient-state single-cell datasets where genes are causally expressed under the control of their regulating transcription factors (TFs).

RNA 40
article thumbnail

Looking beyond traditional oncogenic pathways to break cancer resistance

Drug Target Review

BRAF and downstream mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors are combined to treat BRAF-mutated melanoma, for example. Inhibiting KDM5A, a regulator of cell proliferation, poses another interesting approach.

article thumbnail

Addressing increasingly resistant drugs by infectious agents

Drug Target Review

I had earlier proposed the use of Palmatine and Silver Nitrate in the efficacy against the RNA structure of the COVID-19 virus. 2018): Silent Information Regulator 2 from Trypanosoma cruzi is a potential target to infection control, IntechOpen. 2016): The trypanosome alternative oxidase: a potential drug target? Nilmar, S.

Drugs 111
article thumbnail

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Drug Target Review

Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. 2016 Oct 10;7(1):13119. in North America) in late 2017. Nature Communications. Walling BL, Kim M.

article thumbnail

ATUZAGINSTAT

New Drug Approvals

In addition, older dogs had bacterial antigens and ribosomal RNA in their brains, consistent with systemic infection seen in humans. At CTAD, the company announced plans for a confirmatory trial, pending discussions with regulators. Findings Two Phase 1 trials of atuzaginstat were completed by June 2019. Examples Example 1. mmol, 1.00